英国药品监管风险沟通对处方及临床结局的影响:系统综述、时间序列分析与荟萃分析
该系统综述纳入40项研究,评估25项英国监管风险沟通对处方和健康结局的影响。中断时间序列回归再分析显示,药品撤市、适应证限制和警示信息分别与目标药物处方相对平均变化-78%、-34%和-11%相关。直接医疗专业人员沟通与药品公报的相对变化分别为-47%和-13%;风险沟通与预期健康结局减少10%、非预期健康结局增加7%相关。
要点
- 药品撤市与目标处方相对平均下降78%,适应证限制下降34%,警示信息下降11%。
- 直接医疗专业人员沟通较药品公报带来更大处方变化(-47% vs -13%)。
- 风险沟通与预期健康结局减少10%、非预期健康结局增加7%相关。
核心结论
- 英国监管风险沟通与目标处方显著变化及临床结局潜在变化相关。
- 仍需进一步系统研究监管干预的影响。
研究设计与样本
- 系统综述纳入40项研究,评估25项英国监管风险沟通。
- 采用中断时间序列回归再分析干预后12个月数据,并以随机效应通用逆方差法合并均值变化。
主要发现
- 药品撤市、适应证限制和警示信息与目标药物处方相对平均变化分别为-78%(95%CI -60至-96%)、-34%(95%CI -12至-55%)和-11%(95%CI -8至-15%)。
- 直接医疗专业人员沟通与药品公报的相对平均变化分别为-47%(95%CI -27至-68%)和-13%(95%CI -6至-20%)。
- 7项研究显示风险沟通与预期健康结局平均减少10%(95%CI -3至-16%)、非预期健康结局增加7%(95%CI 4至10%)相关。
临床怎么用
- 关注直接医疗专业人员沟通对处方行为的影响可能大于药品公报。
- 评估监管风险沟通时需同时监测预期和非预期临床结局。
局限性
- 仅纳入英国监管风险沟通相关研究,外推需谨慎。
- 研究间异质性及结局定义差异可能影响合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Regulatory risk communications are important to ensure medication safety, but their impact is poorly understood. The aim was to quantify the impact of UK risk communications on medication use and other outcomes. METHODS: We conducted a systematic review of studies reporting prescribing/health outcome data relevant to UK regulatory risk communication. Data were reanalysed using interrupted time series regression 12 months after each regulatory intervention. Mean changes were pooled using random-effects generic inverse variance examining the following subgroups: drug withdrawals; restrictions/changes in indications; be aware messages without specific recommendations for action; communication via direct healthcare practitioner communications; communication via drug bulletins. RESULTS: Of 11 466 articles screened, 40 studies examining 25 UK regulatory risk communications were included. Product withdrawals, restriction in indications and be aware communications were associated with relative mean changes of -78% (95% confidence interval [CI] -60 to -96%), -34% (95% confidence interval [CI] -12 to -55%) and -11% (95%CI -8 to -15%) in targeted drug prescribing respectively. Direct healthcare professional communications were associated with relative mean changes of -47% (95%CI -27 to -68%) compared to -13% (95%CI -6 to -20%) for drug bulletins. Of 7 studies examining unique health outcomes related to the safety concern, risk communications were associated with a mean -10% (95%CI -3 to -16%) decrease in intended and a 7% (95%CI 4 to 10%) increase in unintended health outcomes. DISCUSSION: UK regulatory risk communications were associated with significant changes in targeted prescribing and potential changes in clinical outcomes. Further research is needed to systematically study the impact of regulatory interventions.
引用
- Weatherburn CJ, Guthrie B, Dreischulte T, et al. Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis. Br J Clin Pharmacol. 2019. PMID: 31465123. doi:10.1111/bcp.14104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。